Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.

MDNA

Medicenna Therapeutics (MDNA)

Medicenna Therapeutics Corp
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:TSX:MDNA
FechaHoraFuenteTítuloSímboloCompañía
26/04/202407:16PR Newswire (Canada)L'Organisme canadien de réglementation des investissements permet la reprise de la négociation - MDNATSX:MDNAMedicenna Therapeutics Corp
26/04/202407:14PR Newswire (Canada)Canadian Investment Regulatory Organization Trade Resumption - MDNATSX:MDNAMedicenna Therapeutics Corp
26/04/202407:09PR Newswire (Canada)Suspension de la négociation par l'Organisme canadien de réglementation des investissements - MDNATSX:MDNAMedicenna Therapeutics Corp
26/04/202407:07PR Newswire (Canada)Canadian Investment Regulatory Organization Trading Halt - MDNATSX:MDNAMedicenna Therapeutics Corp
11/06/202006:00PR Newswire (Canada)Medicenna to Present at Raymond James Human Healthcare Innovation ConferenceTSX:MDNAMedicenna Therapeutics Corp
29/05/202007:15PR Newswire (US)Medicenna Presents Data on MDNA11, an IL-2 Superkine at ASCO 2020TSX:MDNAMedicenna Therapeutics Corp
29/05/202007:05PR Newswire (US)Medicenna Updates Efficacy Results from Phase 2b Recurrent GBM Trial at ASCO 2020TSX:MDNAMedicenna Therapeutics Corp
15/05/202006:30PR Newswire (US)Medicenna Announces March 31, 2020 Year-End ResultsTSX:MDNAMedicenna Therapeutics Corp
04/05/202006:00PR Newswire (Canada)Medicenna Announces Upcoming Presentations at the ASCO Annual MeetingTSX:MDNAMedicenna Therapeutics Corp
15/04/202008:23PR Newswire (Canada)Medicenna Announces Full Exercise of Over-Allotment Option as Part of $40.25 Million Public OfferingTSX:MDNAMedicenna Therapeutics Corp
25/03/202006:00PR Newswire (US)Medicenna's IL-2 Superkine, MDNA19, Demonstrates Best-in-Class Features in a Non-Human Primate StudyTSX:MDNAMedicenna Therapeutics Corp
17/03/202008:14PR Newswire (Canada)Medicenna Announces Closing of Public Offering of $35 MillionTSX:MDNAMedicenna Therapeutics Corp
12/03/202008:00PR Newswire (Canada)Medicenna Announces Intention to File Final Short Form ProspectusTSX:MDNAMedicenna Therapeutics Corp
04/03/202008:37PR Newswire (Canada)L'OCRCVM permet la reprise de la négociation - MDNATSX:MDNAMedicenna Therapeutics Corp
04/03/202008:36PR Newswire (Canada)IIROC Trade Resumption - MDNATSX:MDNAMedicenna Therapeutics Corp
04/03/202008:25PR Newswire (Canada)Medicenna Announces Pricing of $35 Million Overnight Marketed Offering of Common SharesTSX:MDNAMedicenna Therapeutics Corp
03/03/202016:14PR Newswire (Canada)Suspension de la négociation par l'OCRCVM - MDNATSX:MDNAMedicenna Therapeutics Corp
03/03/202016:11PR Newswire (Canada)IIROC Trading Halt - MDNATSX:MDNAMedicenna Therapeutics Corp
03/03/202015:35PR Newswire (Canada)Medicenna Announces Overnight Marketed Offering of Common SharesTSX:MDNAMedicenna Therapeutics Corp
13/02/202006:30PR Newswire (US)Medicenna Reports Third Quarter Fiscal 2020 Financial ResultsTSX:MDNAMedicenna Therapeutics Corp
13/01/202006:00PR Newswire (US)Medicenna Reports Compelling Results from Recurrent Glioblastoma Trial When Compared to an Eligibility-Matched Control ArmTSX:MDNAMedicenna Therapeutics Corp
08/01/202008:13PR Newswire (US)Medicenna Receives $1.3 Million Through Early Warrant ExercisesTSX:MDNAMedicenna Therapeutics Corp
12/12/201907:00PR Newswire (US)Medicenna Presents Additional Encouraging Phase 2b Clinical Data at the Inaugural Glioblastoma Drug Development Annual SummitTSX:MDNAMedicenna Therapeutics Corp
09/12/201906:30PR Newswire (US)Medicenna Announces Presentation of the MDNA55 Clinical Trial at the Inaugural Glioblastoma Drug Development Annual SummitTSX:MDNAMedicenna Therapeutics Corp
25/11/201906:30PR Newswire (US)Medicenna Reports Promising Efficacy in Phase 2b MDNA55 Clinical Trial at the Society for Neuro-Oncology Annual MeetingTSX:MDNAMedicenna Therapeutics Corp
21/11/201907:00PR Newswire (Canada)Medicenna Reports Improved Drug Distribution of MDNA55 with Novel Delivery Technology in Phase 2b Recurrent Glioblastoma Clin...TSX:MDNAMedicenna Therapeutics Corp
20/11/201907:00PR Newswire (US)Medicenna To Host Key Opinion Leader Call Focused on Latest MDNA55 Recurrent Glioblastoma Phase 2b Clinical Study ResultsTSX:MDNAMedicenna Therapeutics Corp
18/11/201906:00PR Newswire (Canada)Medicenna to Host a Key Opinion Leader Symposium on MDNA55 for Treatment of Recurrent GlioblastomaTSX:MDNAMedicenna Therapeutics Corp
14/11/201906:00PR Newswire (US)Medicenna Announces Presentations on MDNA55 Recurrent Glioblastoma Clinical Trial at the Annual Meeting of the Society of Neu...TSX:MDNAMedicenna Therapeutics Corp
05/11/201907:00PR Newswire (Canada)Medicenna Reports Second Quarter Fiscal 2020 Financial ResultsTSX:MDNAMedicenna Therapeutics Corp
 Showing the most relevant articles for your search:TSX:MDNA

Su Consulta Reciente

Delayed Upgrade Clock